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ABSTRACT
Objectives Data suggest a potential role for vitamin D 
in autism spectrum disorder (ASD). We wanted to assess 
the effect of vitamin D3 supplementation compared with 
placebo in children with ASD.
Design This was a double-blind, randomised, placebo-
controlled trial.
Setting A paediatric outpatient centre at high latitude 
over the winter season in Dublin, Ireland (53°N).
Patients 42 children with ASD.
Interventions 2000 IU vitamin D3 supplementation or 
placebo daily for 20 weeks.
Main outcome measures Assessments were 
completed at baseline and after 20 weeks of 
supplementation. The primary outcome was the 
stereotypic behaviour subscale from the Aberrant 
Behaviour Checklist (ABC). Secondary exploratory 
outcomes included additional subscales from the 
ABC, the Social Responsiveness Scale and rating on 
the Developmental Disabilities—Children’s Global 
Assessment Scale (DD-CGAS) as well as biochemical 
parameters of total vitamin D status (25-hydroxyvitamin 
D (25(OH)D)), immunity and systemic inflammation.
Results 38 children completed the trial. Baseline 
25(OH)D was 54.2±19.7 nmol/L. Following vitamin D3 
supplementation, there was a significant increase in 
25(OH)D to 83.8 nmol/L (p=0.0016) but no effect on the 
primary endpoint. However, there was an improvement 
in self-care on DD-CGAS (p=0.02). In contrast, there was 
also a trend toward decreased inappropriate speech in 
the placebo group (p=0.08).
Conclusion Vitamin D supplementation had no effect 
on the primary outcome with limited and inconsistent 
effects in children with ASD. Considering the other 
promising data as well as the relative safety and 
cheapness of vitamin D supplementation, further trials 
are warranted.
Trial registration NCT02508922. 
INTRODUCTION
Autism spectrum disorder (ASD), a complex, 
heterogeneous neurodevelopmental disorder, has 
an estimated prevalence of ~1% in children. ASD 
is associated with significant genetic risk factors. 
However, the impact of environmental factors 
cannot be discounted. Indeed, epigenetic mecha-
nisms have been implicated suggesting that gene–
environment interactions are important in medi-
ating risk.1 2
One potential environmental risk factor for 
ASD is vitamin D deficiency (VDD) which 
affects ~1 billion people.3 While VDD has detri-
mental effects on bone health, recent reports 
suggest implications for neurological, immune and 
inflammatory disorders due to its unique role in 
brain homeostasis, neurodevelopmental and immu-
nological modulation and gene regulation.4–7
Multiple studies have noted inadequate vitamin 
D intake8–11 and/or status11–21 in children with 
ASD. Indeed, a 2016 meta-analysis of 11 studies, 
including 870 ASD children and 782 typi-
cally developing children, demonstrated signifi-
cantly lower 25-hydroxyvitamin D (25(OH)D) in 
ASD compared with controls.22
Recent reviews have detailed the associations 
between vitamin D and ASD.4–7 23 VDD has been 
implicated in the development of ASD symptoms 
in an animal model.24 Low-level evidence based on 
a single case report25 and two open-label studies 
support the role of vitamin D supplementation 
in ASD.26 27 Additionally, a single, double-blind, 
randomised, placebo-controlled trial reported 
benefit of supplementation in ASD.28 However, any 
potential mechanisms mediating a positive effect of 
vitamin D supplementation in ASD remain obscure. 
Therefore, we wanted to rigorously assess the 
effects of vitamin D3 supplementation in ASD.
METHODS
This trial was conducted at the National Children’s 
Hospital (Dublin, Ireland) following institutional 
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What is already known on this topic?
 ► Autistic children are at risk for low vitamin D 
intakes and status.
 ► Vitamin D is hypothesised to have neurological, 
immunomodulatory and anti-inflammatory 
roles, which may be relevant in autism.
 ► Recent animal model and open-label studies as 
well as a double-blind, randomised, placebo-
controlled trial suggest benefit of vitamin D 
supplementation. 
What this study adds?
 ► We present one of first randomised controlled 
trials of vitamin D supplementation in autism. 
 ► Vitamin D status increased significantly, but 
there was no effect on stereotypical behaviour 
as assessed with Aberrant Behaviour Checklist 
(primary endpoint). 
 ► We did observe some benefits, but this 
was inconsistent and further trials are 
recommended. 
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review board approval. At baseline, trial information was 
provided, and written parental/guardian consent was obtained 
prior to study procedures.
Subjects
ASD children were recruited from paediatric neurodevelop-
mental and general outpatient clinics as well as through commu-
nity ASD services. Inclusion criteria included clinician-diagnosed 
ASD (by either Autism Diagnostic Observation Schedule, Diag-
nostic and Statistical Manual of Mental Disorders or Diagnostic 
Instrument for Social and Communication Disorders), Social 
Communication Questionnaire (SCQ) score >15, aged <18 
years and medically stable. Exclusion criteria included non-de-
finitive ASD diagnosis, conditions/medications that influence 
vitamin D metabolism or absorption (including epilepsy), 
vitamin A supplementation (including cod liver oil) and chronic, 
non-autistic medical issues.
Supplements
At baseline, each parent/guardian was provided with eight 
bottles of drops containing either vitamin D3 or identical placebo 
in a double-blind, randomised, age and gender balanced ratio. A 
physician not involved in data gathering (DC) generated the allo-
cation sequence, while a nutrition researcher enrolled subjects 
(CPK). Parents/guardians were instructed to administer 20 drops 
daily for 20 weeks to their child with food (2 000 IU).
Diet, supplement use and particularly exposure to ultravi-
olet B radiation contribute to vitamin D status. Therefore, we 
conducted this trial at high latitude (53°N) during winter season 
when skin vitamin D synthesis is minimal. Further, we advised 
recruits not to change dietary/supplemental behaviours during 
the trial. We assessed behaviour relating to vitamin D status with 
the VIDSun questionnaire at baseline and endpoint.29 Supple-
ment compliance was assessed with a diary and by returning the 
bottles of drops at the follow-up visit.
Study design
This was a parallel, randomised, double-blind, placebo-con-
trolled trial and involved two clinic visits (figure 1). Recruit-
ment occurred between September and December 2015, with 
follow-up 20 weeks later. All assessments were conducted at 
baseline and follow-up. Following completion of day 1  presup-
plementation assessments, subjects were randomised to vitamin 
D3 (D3) or placebo (PL) groups using an online randomisation 
programme.
Assessments
We used a combination of commonly used parental and clinician 
subjective autistic measures and biochemical indices.
Aberrant Behaviour Checklist (ABC)
The ABC, a 58-item informant (eg, parent) rating scale, includes 
five subscales: irritability, lethargy/social withdrawal, 
Figure 1 Trial design. *Assessments included subjective autism spectrum disorder measures and blood draw. D3, vitamin D3; PL, placebo.
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stereotypical behaviour, hyperactivity/non-compliance and 
inappropriate speech. Higher scores indicate greater severity of 
problem behaviours. ABC is clinically relevant, is sensitive to 
change, was designed to measure treatment effects and has been 
used extensively in ASD.30 Therefore, we selected the stereo-
typical behaviour subscale of the ABC as our primary endpoint.
The Social Responsiveness Scale (SRS)
SRS is another clinically relevant, commonly used, informant 
rating scale in ASD research.
The Developmental Disabilities—Children’s Global Assessment Scale 
(DD-CGAS)
DD-CGAS is a clinician-rated instrument designed to estimate 
global functioning of the child during the past month across 
all domains of functioning (self-care, communication, social 
behaviour and academic functioning).
Biochemistry
Venous blood samples were collected at baseline and endpoint 
and analysed locally for complete blood count, 25(OH)D and 
C reactive protein (CRP), as well as renal, liver and bone profiles.
We assessed vitamin D status by measuring total serum 25(OH)
D. The rationale for measuring 25(OH)D and the methods have 
been described previously.31 We dichotomised 25(OH)D levels 
based the most recent Institute of Medicine (IOM) recommen-
dations where <50 nmol/L indicates VDD and >50 nmol/L indi-
cates vitamin D sufficiency (VDS).32
Statistics
For this trial, the stereotypical behaviour subscale from ABC 
served as the primary outpoint. We calculated that a sample size 
of 34 (17 to each group) would provide 81% power at the 0.05 
significance level based on an SD of 5.6126 to detect a treat-
ment difference 5.7.26 We factored in a drop-out rate of 15% 
and therefore recruited 42 ASD subjects. All data were normally 
distributed results and expressed as mean±SD. Paired t-tests 
were used to assess differences within groups between variables, 
while unpaired t-tests were used to assess differences between 
groups. Pearson’s coefficient was used for correlation analysis. 
p<0.05 was considered statistically significant. Statistical anal-
ysis was performed using a software package (SPSS, version 18).
RESULTS
We screened 270 children for eligibility. Of these, 64 children 
were eligible, but only 42 children provided consent, were 
recruited and completed baseline assessments (figure 1).
Baseline findings
All 42 recruited children completed all baseline measures (38 
male, mean age 7.1 years; mean body mass index (BMI) 17.6 kg/
m2). Mean 25(OH)D was 54.2 nmol/L (range: 15–101 nmol/L). 
According to the IOM guidelines, 17 children were VDD (40%), 
while 25 were VDS. There were no significant differences in 
demographics (age and BMI) or serum biomarkers between the 
VDD and VDS groups.
Using balanced randomisation, children assigned to placebo 
were well matched to those assigned to vitamin D3. However, 
there were trends toward higher lethargy scores in the D3 group 
but lower scores for inappropriate speech and social behaviour.
Follow-up results
Of the 42 recruits, four children dropped out due to inconve-
nience of scheduled visits (figure 1) (all from the vitamin D3 
group). Therefore, 38 children completed the trial (table 1).
Compliance with trial supplements was high in both groups 
(>95%) as assessed with a diary and by examining the bottles of 
drops at follow-up. No adverse effects were reported.
Table 2 displays a comparison of changes in means after 20 
weeks. As expected, after 20 weeks of vitamin D3 supplemen-
tation, there was a significant increase in 25(OH)D compared 
with PL (p=0.0016), but no change in VIDSun score in either 
group. No effect was observed on the primary endpoint (stereo-
typical behaviour subscale of the ABC). A significant improve-
ment was observed in self-care score on DD-CGAS in D3 versus 
PL (p=0.02). A non-significant decrease in inappropriate speech 
was observed in PL versus D3 (p=0.08). No other significant 
between group differences were observed for the behavioural 
measurements.
25(OH)D decreased in a single child in the vitamin D supple-
mentation arm (−9 nmol/L) and did not change in a second 
child. Furthermore, 25(OH)D did not change in two chil-
dren and actually increased in nine children in the PL group 
(+1 to +45 nmol/L). Therefore, we analysed the results based 
on 25(OH)D response (table 3). There was a greater improve-
ment in total SRS score in those with increased 25(OH)D. In 
contrast, there was a greater improvement in total ABC and ABC 
subscales in those with decreased 25(OH)D. The three children 
who had no change in 25(OH)D levels also displayed improve-
ments on ABC, SRS and DD-CGAS.
Table 1 Baseline demographics
Placebo Vitamin D p Value*
n 20 18
Age (years) 6.9±3.8 7.9±23.4 0.41
Male, n (%) 18 (90) 15 (83) –
BMI (kg/m2) 17.7±3.9 18.1±2.9 0.69
SCQ 20.2±3.8 19.6±3.1 0.76
ABC
  Irritability 14.1±10.8 14.8±10.8 0.81
  Lethargy 10.2±6.3 13.4±7.5 0.08
  Stereotypy 7.8±5.2 6.7±4.4 0.5
  Hyperactivity 18.6±11.9 19.1±7.9 0.86
  Inappropriate 
speech
5.4±3.8 4.2±2.2 0.3
  Total 55.9±32.8 58.3±21.5 0.78
SRS
  Total 150±25.2 149.1±27.2 0.89
DD-CGAS
  Self-care 47±19.1 39.1±20.92 0.24
  Communication 46.5±17.3 40.9±18 0.34
  Social behaviour 50.5±15.7 42.6±16.4 0.15
  School/academic 46.5±17.6 43.2±22.9 0.63
Biochemistry
  CRP (mg/L) 2.7±5.7 1.1±0.4 0.27
  Ca2+ (mmol/L) 2.3±0.06 2.33±0.07 0.36
  25(OH)D (nmol/L) 51.7±19.8 58.4±17.9 0.3
*p Values were derived using two-tailed, independent-samples t-tests.
25(OH)D, 25-hydroxyvitamin D; ABC, Aberrant Behaviour Checklist; BMI, body 
mass index; Ca2+, albumin-corrected calcium; CRP, C reactive protein; DD-CGAS, 
Developmental Disabilities—Children’s Global Assessment Scale; SRS, Social 
Responsiveness Scale.
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Because it has been hypothesised that vitamin D supplemen-
tation may be most beneficial regarding ASD in early life,26 
27 we analysed results based on age. Although irritability 
improved significantly more in those <6 years compared 
with those >6 years (p=0.04), there were no other signifi-
cant differences, including stereotypical behaviour (primary 
endpoint).
Table 4  presents the correlation coefficients between ABC, 
SRS and DD-CGAS parameters versus 25(OH)D at both baseline 
and follow-up. We observed only a single significant correlation 
Table 2 Subjective and biochemical results before and after the trial
Placebo Vitamin D p Value*
n 20 18
Pre Post Δ Pre Post Δ
ABC
  Irritability (0–45) 14.1 9 −5.1 14.8 12.3 −3.5 0.45
  Lethargy (0–48) 10.2 5.6 −4.6 13.4 10.2 −3.2 0.88
  Stereotypical behaviour (0–21) 7.8 4.8 −3 6.7 5.9 −0.8 0.28
  Hyperactivity (0–48) 18.6 13.3 −5.3 19.2 15.7 −3.5 0.63
  Inappropriate speech (0–12) 5.4 2.9 −2.5 4.2 4.1 −0.1 0.08
  Total 55.9 35.5 −20.4 58.3 48.2 −10.1 0.2
SRS
  Total (0–260) 150.3 137.6 −12.7 149.1 124.8 −24.6 0.48
DD-CGAS
  Self-care (0–100) 47 54.5 7.5 39.1 59.4 20.3 0.02
  Communication (0–100) 46.5 57.5 11 40.8 52.6 11.8 0.6
  Social behaviour (0–100) 50.5 56.3 5.8 40.6 55.6 5 0.38
  School/academic (0–100) 46.5 59.5 13 43.2 51.2 8 0.24
Biochemistry
  CRP (mg/L) 2.7 1.5 −1.2 1.1 1.3 0.2 0.4
  Neutrophil:lymphocyte 1.1 1.2 0.1 1 1.3 0.3 0.58
  Ca2+ (mmol/L) 2.3 2.33 0.03 2.3 2.3 0 0.26
  25(OH)D (nmol/L) 51.7 50.6 −1.1 58.5 86.1 27.6 0.0016
*p Values derived from unpaired t-tests.
25(OH)D, 25-hydroxyvitamin D; ABC, Aberrant Behaviour Checklist; Ca2+, albumin-corrected calcium; CRP, C reactive protein; DD-CGAS, Developmental Disabilities—Children’s 
Global Assessment Scale; SRS, Social Responsiveness Scale.
Table 3 Per cent change in parameters according to 25(OH)D 
response
Decreased 
25(OH)D
Unchanged 
25(OH)D
Increased 
25(OH)D
n 10 3 24
PL allocation 9 2 9
D3 allocation 1 1 15
ABC
  Irritability (0–45) −38 2 −4
  Lethargy (0–48) −56 −5 −4
  Stereotypical behaviour (0–21) −59 −2 −2
  Hyperactivity (0–48) −42 −4 −3.5
  Inappropriate speech (0–12) −53 0 −1
  Total (0–174) −49 -9 −13
SRS
  Total −14 −1 −23
DD-CGAS
  Self-care (0–100) 12 17 14
  Communication (0–100) 25 17 10
  Social behaviour (0–100) 20.7 −18 10
  School/academic (0–100) 27 7 11
Biochemistry
  CRP (mg/L) 10 −9 0.1
  Neutrophil:lymphocyte 0.2 −1 0.1
  Ca2+ (mmol/L) 2 −0.01 0.1
  25(OH)D (nmol/L) −37 0 25
25(OH)D, 25-hydroxyvitamin D; ABC, Aberrant Behaviour Checklist; Ca2+, albumin-
corrected calcium; CRP, C reactive protein; DD-CGAS, Developmental Disabilities—
Children’s Global Assessment Scale; PL, placebo; SRS, Social Responsiveness Scale.
Table 4 Correlations between ASD parameters and 25(OH)D
Baseline Follow-up
ABC
  Irritability 0.29 0.27
  Lethargy 0.12 0.04
  Stereotypical behaviour 0.18 0.14
  Hyperactivity 0.36* 0.19
  Inappropriate speech 0.17 0.14
  Total 0.3 0.2
SRS
  Total 0.2 0.04
DD-CGAS
  Self-care (0–100) 0.006 0.139
  Communication −0.28 −0.06
  Social behaviour −0.003 0.12
  School/academic −0.16 0.06
*Significant (p=0.018).
25(OH)D, 25-hydroxyvitamin D; ABC, Aberrant Behaviour Checklist; DD-CGAS, 
Developmental Disabilities—Children’s Global Assessment Scale; SRS, Social 
Responsiveness Scale.
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with baseline 25(OH)D and no significant relationships with 
follow-up 25(OH)D.
DISCUSSION
We present one of the first randomised, double-blind, place-
bo-controlled trials of vitamin D in ASD. We investigated the 
effect of vitamin D3 supplementation (2000 IU/day) for 20 weeks 
among a small sample of urban, mostly Caucasian children with 
clinician-diagnosed ASD at high latitude over winter season. 
In contrast to most11 26 27 but not all previous reports,21 there 
was no difference between VDD and VDS groups regarding 
ASD parameters at baseline. There was a significant increase in 
vitamin D status in the D3 group. However, there was no effect 
on the prespecified primary endpoint: stereotypical behaviour 
subscale from ABC.
A significant improvement was observed in a single, explor-
atory outcome (self-care score) with vitamin D supplementation. 
A non-significant improvement was observed in another single, 
exploratory outcome (decreased inappropriate speech) in the 
PL group. These contradictory observations are likely stochastic 
or statistical artefact. There were no other observed differences 
between groups.
In the vitamin D arm, 25(OH)D decreased in a single child 
and did not change in a second child. Although reported compli-
ance with the supplements was high, this could nevertheless be 
explained by non-compliance (we did not objectively measure 
compliance). Other explanations include measurement error 
or absorption issues. We cannot rule out an absorption/meta-
bolic issue with vitamin D which is supported by a recent small 
study where 25(OH)D was significantly lower in 42 ASD chil-
dren compared with 40 typically developing children (p<0.001) 
despite similar sun exposure and oral intake.33 Furthermore, 
despite conducting this trial at high latitude over the winter 
season and the lack of change in VIDSun scores, 25(OH) 
remained constant in two children and actually increased in nine 
children in the PL group (+1 to +45 nmol/L). This could possibly 
reflect commencement of non-trial vitamin D supplementation 
or skin photosynthesis of vitamin D, since follow-up occurred in 
mid-late spring. Based on these observations, we further analysed 
results based on 25(OH)D response, which revealed inconsistent 
results. We also conducted regression analysis, which revealed 
only a single significant relationship (out of 22), again suggesting 
a stochastic or statistical artefact. Collectively, our results suggest 
that there was no benefit of vitamin D3 supplementation in 
ASD compared with placebo. Furthermore, improvements in 
the children whose 25(OH)D level either decreased or did not 
change suggest a significant placebo effect. The placebo effects 
pose significant challenges in ASD regarding reliable detection 
of a treatment response. A recent study simulated a clinical trial 
with baseline and endpoint assessments but no treatment, yet 
caregivers reported ABC and SRS improvements.34
In addition to multiple reports of inadequate vitamin D 
intake8–11 and/or vitamin D status11–21 in ASD, detailed in 
vitro and in silico work has demonstrated that relevant genes 
(eg, THP2 gene) and brain hormones (serotonin, oxytocin and 
vasopressin) are directly regulated by calcitriol, also known as 
1,25-dihydroxyvitamin D3 (1,25D),23 35 36 implying that VDD 
may have a role in ASD. Furthermore, an early report of vitamin 
D supplementation providing protective and restorative effects 
on ASD features in rat pups24 increased interest in the therapeutic 
potential of vitamin D for ASD. This was followed by a case 
study reporting improvement of core ASD symptoms following 
150 000 IU/month for 2 months+400 IU/day in a 32 month-old 
Chinese boy with VDD and ASD.25 Subsequently, two open-
label studies were published. An Egyptian study reported that 
67 of 83 VDD children with ASD (81%) had improved ABC 
and childhood autism rating scale following vitamin D3 supple-
mentation (300 IU/day/kg of body weight) for 12 weeks.26 
Another open-label study from China assessed 37 VDD children 
before and after monthly intramuscular vitamin D3 (150 000 IU) 
and daily oral vitamin D3 (400 IU). Total ABC and SRS scores 
were reduced significantly after 12 weeks.27 Additionally, a 
very recent, double-blind, randomised, placebo-controlled trial 
consisted of 109 ASD children (3–10 years) randomised to 
daily vitamin D (300 IU/kg of body weight but ≤5000 IU) or 
placebo for 4 months. Vitamin D supplementation significantly 
improved ABC, SRS, childhood autism rating scale and Autism 
Treatment Evaluation Checklist scores.28 Although there were 
many similarities between our trial and this other trial, there are 
several notable differences. Our cohort were older (mean age 
7.4 vs 5.4 years), had lower ABC scores (and perhaps milder 
ASD) and had lower baseline 25(OH)D (54.2 versus 66 nmol/L). 
Furthermore, the change in 25(OH)D was lower in our trial 
(+25 versus +49 nmol/L) resulting in a much lower 25(OH)D 
level at follow-up (83.8 versus 114.8 nmol/L).
Trial strengths
We used the gold standard study design and assessed a combi-
nation of widely used subjective assessments and biochemical 
markers. The PL and vitamin D groups were well matched 
at baseline with no significant differences in demographics, 
including 25(OH)D.
Vitamin D trials can be influenced by a number of factors, 
including fluctuations in sun exposure, variable quality of vitamin 
D assays, compliance with the intervention and provision of 
inadequate vitamin D supplementation doses. To overcome these 
factors, we conducted this trial over the winter season at high 
latitude when vitamin D photosynthesis is minimal. Although we 
purposely did not restrict non-protocol dietary or supplemental 
vitamin D intake, we did ask that such behaviours were not 
altered during the trial. Vitamin D behaviours were similar in 
both groups throughout the trial. We used the current gold stan-
dard assay for total 25(OH)D. Reported supplement compliance 
was high. We used a moderate-to-high dose of vitamin D3 (2000 
IU/day) Finally, comorbidities and medication use were rare in 
both groups. Furthermore, there was no change in non-trial 
medication/therapy/supplementation.
Trial limitations
Limitations of our study include the relatively small number of 
subjects. We used fixed vitamin D dosing, but it may be more 
appropriate to titrate vitamin D dosing based on baseline 
25(OH)D levels and/or body size.24 26 28
We did not selectively recruit VDD children. However, any 
detrimental effect of low 25(OH)D may be most apparent when 
comparing VDD with VDS. In this trial, mean baseline 25(OH)
D was 54.2 nmol/L (range: 15–101 nmol/L). Only 17 children 
were VDD (40%). However, previous open-label studies26 27 and 
a randomised controlled trial also included subjects who were 
not VDD28 which all demonstrated benefit of vitamin D supple-
mentation.
Although 25(OH)D is considered the best circulating 
biomarker of vitamin D status, there are many important metab-
olites and intermediates in the vitamin D metabolic pathway. 
For example, paternal37 and individual38 39 vitamin D receptor 
(VDR) polymorphisms have been associated with increased ASD 
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risk. We did not measure levels of vitamin D-binding protein, 
VDR or calcitriol (1,25D) which may have provided interesting 
insight here.
Stereotypical behaviour was selected as the primary outcome 
measure based on a single, open-label study reported prior to 
the design of this study.26 To our knowledge, there are no mech-
anisms by which vitamin D could specifically improve stereo-
typical behaviour. However, another recent trial also reported a 
significant improvement in stereotypical behaviour in ASD after 
vitamin D supplementation.28
It is possible that we studied children who were too old to gain 
neurodevelopmental benefit from vitamin D supplementation. 
Furthermore, vitamin D supplementation has been suggested to 
have primary prevention potential regarding ASD.38–44 Further-
more, vitamin D supplementation has been suggested to have 
primary prevention potential regarding ASD.38 43 Although we 
analysed results based on age (ie, <6 vs 6 years), vitamin D 
treatment effects have been reported to be more pronounced in 
younger children (<3 years) with ASD27 leading to the sugges-
tion that vitamin D supplementation should start in early infancy 
or during gestation.26 27 39–44 In this context, it is possible that 
there is a window of opportunity for adequate 25(OH)D to 
provide neuroprotection and that we included older children 
in whom neuronal networks are established and therefore less 
likely to benefit from supplementation (mean age in vitamin D 
group 7.9 years).
Finally, it is possible that a higher dose of vitamin D would 
produce a greater change in both 25(OH)D and ASD behaviour. 
Some reports have demonstrated selective success with vitamin 
D supplementation when 25(OH)D exceeds 100 nmol/L.26 
28 In this study, only five children (13%) obtained a 25(OH)
D >100 nmol/L.
CONCLUSIONS
Our results do not support supplementary vitamin D for chil-
dren with ASD. Considering preliminary interventional studies 
of 8–16 weeks26–28 as well as the extent of vitamin D deficiency 
in ASD and the low cost and high benefit to risk ratio of vitamin 
D supplementation, larger and preferably longer trials, perhaps 
focusing on primary prevention and/or younger children as well 
as relevant mechanisms and optimal dose/duration of supple-
mentation/25(OH)D levels with ASD, are warranted.
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